Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$59.55 -4.2%	$61.01	$43.70 ▼ $86.53	$1.90B	-1.44	47,436 shs	21,092 shs
IDYA IDEAYA Biosciences	$22.18 -0.4%	$18.94	$13.45 ▼ $44.42	$1.94B	0.04	1.03 million shs	862,850 shs
SDGR Schrödinger	$21.43 -6.1%	$23.64	$16.60 ▼ $28.47	$1.57B	1.63	896,770 shs	1.73 million shs
TRML Tourmaline Bio	$19.68 -1.1%	$16.23	$11.56 ▼ $29.79	$505.48M	2.05	274,816 shs	154,595 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-4.17%	-0.22%	-3.33%	-11.70%	+19.16%
IDYA IDEAYA Biosciences	-0.45%	+2.07%	+29.71%	+19.38%	-43.72%
SDGR Schrödinger	-6.13%	-12.96%	-10.41%	-6.42%	-0.97%
TRML Tourmaline Bio	-1.11%	+2.13%	+26.97%	+4.68%	+21.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.797 of 5 stars	3.5	3.0	0.0	3.9	0.8	0.6
IDYA IDEAYA Biosciences	3.8548 of 5 stars	3.5	2.0	4.4	2.8	1.7	0.0
SDGR Schrödinger	2.465 of 5 stars	3.5	1.0	0.0	3.0	2.5	0.6
TRML Tourmaline Bio	2.8433 of 5 stars	3.5	3.0	0.0	3.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	62.33% Upside
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$54.27	144.69% Upside
SDGR Schrödinger	3.00	Buy	$32.80	53.06% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	150.68% Upside

Current Analyst Ratings Breakdown

Latest TRML, IDYA, BLTE, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
4/16/2025	SDGR Schrödinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $32.00
3/26/2025	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/18/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/18/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
3/14/2025	TRML Tourmaline Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$3.28 per share	N/A
IDYA IDEAYA Biosciences	$7M	277.51	N/A	N/A	$12.10 per share	1.83
SDGR Schrödinger	$230.49M	6.82	$0.57 per share	37.42	$7.60 per share	2.82
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$31.63M	-$1.36	N/A	N/A	N/A	N/A	-31.94%	-30.73%	8/8/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-26.74%	-25.54%	8/5/2025 (Estimated)
SDGR Schrödinger	$40.72M	-$2.63	N/A	N/A	N/A	-91.84%	-35.77%	-24.51%	7/30/2025 (Estimated)
TRML Tourmaline Bio	-$42.12M	-$3.21	N/A	N/A	N/A	N/A	-20.97%	-20.56%	8/6/2025 (Estimated)

Latest TRML, IDYA, BLTE, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	SDGR Schrödinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A
3/17/2025	Q4 2024	BLTE Belite Bio	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
SDGR Schrödinger	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	30.73	30.73
IDYA IDEAYA Biosciences	N/A	14.97	22.93
SDGR Schrödinger	N/A	4.11	4.11
TRML Tourmaline Bio	N/A	40.33	40.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
IDYA IDEAYA Biosciences	98.29%
SDGR Schrödinger	79.05%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
IDYA IDEAYA Biosciences	2.50%
SDGR Schrödinger	8.60%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
IDYA IDEAYA Biosciences	80	87.58 million	84.47 million	Optionable
SDGR Schrödinger	790	73.38 million	66.59 million	Optionable
TRML Tourmaline Bio	44	25.69 million	22.82 million	Optionable

TRML, IDYA, BLTE, and SDGR Headlines

Recent News About These Companies

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

June 10, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE

June 6, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Trading Up 7.2% - Here's What Happened

June 5, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from Brokerages

May 31, 2025 | marketbeat.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 28, 2025 | marketbeat.com

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings

May 27, 2025 | marketbeat.com

29,844 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Purchased by Rafferty Asset Management LLC

May 25, 2025 | marketbeat.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Wexford Capital LP Purchases New Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 22, 2025 | marketbeat.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Stake Increased by Velan Capital Investment Management LP

May 21, 2025 | marketbeat.com

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 21, 2025 | fiercebiotech.com

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 21, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRML, IDYA, BLTE, and SDGR Company Descriptions

Belite Bio NASDAQ:BLTE

$59.55 -2.59 (-4.17%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$59.45 -0.10 (-0.17%)

As of 06/13/2025 04:02 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

IDEAYA Biosciences NASDAQ:IDYA

$22.18 -0.10 (-0.45%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.96 -0.22 (-0.99%)

As of 06/13/2025 05:09 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Schrödinger NASDAQ:SDGR

$21.43 -1.40 (-6.13%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.43 +0.00 (+0.02%)

As of 06/13/2025 07:47 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Tourmaline Bio NASDAQ:TRML

$19.68 -0.22 (-1.11%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$19.68 +0.00 (+0.03%)

As of 06/13/2025 04:25 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time